Continuous vs. Intermittent Infusion Vancomycin

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexander Flannery
• Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

1. ≥ 18 years of age

2. Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care)

3. Prescribed ≥ 2 doses of vancomycin per treating physician

4. Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent.

Exclusion Criteria:

1. Chronic kidney disease (documented or prior to admission eGFR <60 ml/min/1.73m2 using non-race-based creatinine GFR equation)

2. End stage kidney disease

3. Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase ≥ 0.3 mg/dl or 1.5-1.9 times baseline; urine output < 0.5 ml/kg/hr for 6-12 hours)

4. Receipt of vancomycin within the last 72 hours (not considering the loading dose)

5. Allergy to iohexol

6. Uroepithelial tumors

7. Pregnancy

8. Prisoner